TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial (Q42623198)
Jump to navigation
Jump to search
scientific article published on October 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial |
scientific article published on October 2013 |
Statements
1 reference
TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial (English)
1 reference
1 reference
Charles S Fuchs
1 reference
Marwan Fakih
1 reference
Lee Schwartzberg
1 reference
Allen L Cohn
1 reference
Lorrin Yee
1 reference
Luke Dreisbach
1 reference
Mark F Kozloff
1 reference
Yong-jiang Hei
1 reference
Francesco Galimi
1 reference
Yang Pan
1 reference
Vincent Haddad
1 reference
Cheng-Pang Hsu
1 reference
Antony Sabin
1 reference
1 October 2013
1 reference
1 reference
119
1 reference
24
1 reference
4290-4298
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference